0059 GMT - The steep fall in Monash IVF's share price following another incident at one of its laboratories has raised the chances of it becoming a takeover target, reckons Ord Minnett. Monash IVF's share price fell by around 1/4 after it disclosed a new incident at its Clayton laboratory in southeastern Australia. That extended a stock decline that happened after an earlier incident in Brisbane. Monash IVF's CEO has since resigned. Analyst Tom Godfrey says these developments have heightened risks including weaker new patient volumes, potential doctor losses and increased regulation. "With Monash IVF now trading at 6.7x adjusted Ebitda (versus competitors at >12x) we see increased risk of Private equity/strategic interest," Ord Minnett says. Monash IVF is up 1.5% at A$0.67. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 12, 2025 20:59 ET (00:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。